On February 16, 2024, Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate. Pursuant and subject to the terms of the merger agreement, a wholly owned subsidiary of XOMA will commence a tender offer by March 4, 2024 to acquire all outstanding shares of Kinnate common stock. The merger transaction is expected to close in the first half of 2024. Wilson Sonsini Goodrich & Rosati is advising Kinnate on the transaction.

Kinnate concentrates its efforts on addressing known oncogenic drivers for which there are currently no approved targeted therapies and to overcome the limitations associated with existing cancer therapies, such as non-responsiveness or the development of acquired and intrinsic resistance. The company’s lead product candidates are investigational pan-RAF inhibitor, exarafenib, which targets cancers with BRAF and NRAS-driven alterations, and investigational FGFR inhibitor, KIN-3248, which is designed for cancers with FGFR2 and FGFR3 alterations.

The Wilson Sonsini team advising Kinnate Biopharma on the transaction includes:

M&A
Robert Ishii
Brendan Mahan
David Adler
Eric Chang
Cindy West

Corporate
Tony Jeffries
Lance E. Brady
Jennifer Knapp
Zack Lenox

Technology Transactions
Miranda Biven
Norm Hovijitra
Colin Bosch

Patents and Innovations
Mike Hostetler
Deborah Smith
Kyle Headrick
David Clark

Privacy and Cybersecurity
Matt Staples
Michael O’Brien
Diya Jajal

Tax
Myra Sutanto Shen
Brandon M. King
Beau Brawner

Employee Benefits and Compensation
Sriram Krishnamurthy
Gregory Hughes
Jason Chan
Emma Wilcox

Employment
Marina Tsatalis
Alison Renner
Heather Diles

Regulatory
Eva Yin
Seth Cowell
Anne Seymour
Joshua Gruenspecht
Tarek Helou

For more information, please see Kinnate Biopharma’s press release.